



**CLAIMS:**

1. Compounds according to the Formula (Ia) and/or (Ib):



wherein

X is selected from



$R^1$  is selected from H, halogen,  $C_{1-6}$ -alkyl, halo- $C_{1-6}$ -alkyl, hydroxy- $C_{1-6}$ -alkyl,  $C_{3-6}$ -cycloalkyl, halo- $C_{3-6}$ -cycloalkyl, -O- $C_{1-6}$ -alkyl, -O-halo- $C_{1-6}$ -alkyl and -NH- $C_{1-6}$ -alkyl;

15  $R^2$  is selected from H, -CN, -NO<sub>2</sub>,  $C_{1-10}$ -alkyl,  $C_{2-10}$ -alkenyl,  $C_{2-10}$ -alkynyl,  $C_{0-10}$ -alkylene- $C_{3-10}$ -cycloalkyl,  $C_{0-10}$ -alkylene- $C_{3-10}$ -heterocycloalkyl,  $C_{0-10}$ -alkylene-(5- to 10-membered heteroaryl),  $C_{0-10}$ -alkylene-(6- to 10-membered aryl),  $C_{0-10}$ -alkylene-(6- to 10-membered heteroaryl),  $C_{0-10}$ -alkylene-OR<sup>11</sup>,  $C_{0-10}$ -alkylene-CO<sub>2</sub>R<sup>11</sup>,  $C_{0-10}$ -alkylene-C(=O)NR<sup>11</sup>R<sup>12</sup>,  $C_{0-10}$ -alkylene-C(=S)NR<sup>11</sup>R<sup>12</sup>,  $C_{0-10}$ -alkylene-C(=O)NR<sup>11</sup>SO<sub>2</sub>R<sup>13</sup>,  $C_{0-10}$ -alkylene-C(=S)NR<sup>11</sup>SO<sub>2</sub>R<sup>11</sup>,  $C_{0-10}$ -alkylene-C(=O)R<sup>11</sup>,  $C_{0-10}$ -alkylene-C(=S)R<sup>11</sup>,  $C_{0-10}$ -alkylene-SR<sup>11</sup>,  $C_{0-10}$ -alkylene-SO<sub>x</sub>R<sup>13</sup>,  $C_{0-10}$ -alkylene-SO<sub>3</sub>R<sup>11</sup>,  $C_{0-10}$ -alkylene-SO<sub>2</sub>NR<sup>11</sup>R<sup>12</sup>,  $C_{0-10}$ -alkylene-NR<sup>11</sup>C(=O)R<sup>11</sup>,  $C_{0-10}$ -alkylene-NR<sup>11</sup>C(=S)R<sup>11</sup>,  $C_{0-10}$ -alkylene-NR<sup>11</sup>SO<sub>2</sub>R<sup>13</sup>,  $C_{0-10}$ -alkylene-NR<sup>11</sup>C(=O)NR<sup>11</sup>R<sup>12</sup>,  $C_{0-10}$ -alkylene-NR<sup>11</sup>C(=S)NR<sup>11</sup>R<sup>12</sup>,  $C_{0-10}$ -alkylene-NR<sup>11</sup>SO<sub>2</sub>NR<sup>11</sup>R<sup>12</sup>,  $C_{0-10}$ -alkylene-NR<sup>11</sup>R<sup>12</sup>, wherein alkyl, alkenyl, alkynyl, alkylene, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is unsubstituted or substituted with 1 to 7 substituents independently selected from the group consisting of oxo, CN, -NO<sub>2</sub>, OR<sup>11</sup>, O- $C_{2-6}$ -alkylene-OR<sup>11</sup>,  $C_{1-6}$ -alkyl, halo- $C_{1-6}$ -alkyl, halogen, CO<sub>2</sub>R<sup>11</sup>, C(=O)NR<sup>11</sup>R<sup>12</sup>, C(=O)NR<sup>11</sup>SO<sub>2</sub>R<sup>11</sup>, C(=O)R<sup>11</sup>, SR<sup>11</sup>, SO<sub>x</sub>R<sup>11</sup>, SO<sub>3</sub>R<sup>11</sup>, P(=O)(OR<sup>11</sup>)<sub>2</sub>, SO<sub>2</sub>NR<sup>11</sup>R<sup>12</sup>, NR<sup>11</sup>C(=O)R<sup>11</sup>, NR<sup>11</sup>SO<sub>2</sub>R<sup>13</sup>, NR<sup>11</sup>C(=O)NR<sup>11</sup>R<sup>12</sup>, NR<sup>11</sup>SO<sub>2</sub>NR<sup>11</sup>R<sup>12</sup>,  $C_{3-10}$ -cycloalkyl, O- $C_{3-10}$ -cycloalkyl,  $C_{3-10}$ -heterocycloalkyl, O- $C_{3-10}$ -heterocycloalkyl and NR<sup>11</sup>R<sup>12</sup>;

20

25

30

- $R^3$  is selected from H,  $C_{1-6}$ -alkyl, halo- $C_{1-6}$ -alkyl, -O- $C_{1-6}$ -alkyl, -O-halo- $C_{1-6}$ -alkyl,  $C_{3-6}$ -cycloalkyl and  $C_{3-6}$ -heterocycloalkyl, wherein alkyl, cycloalkyl and heterocycloalkyl are optionally substituted with 1 to 5 substituents independently selected from halogen, -CN, OH, oxo,  $C_{1-3}$ -alkyl, halo- $C_{1-3}$ -alkyl, O- $C_{1-3}$ -alkyl, O-halo- $C_{1-3}$ -alkyl,  $SO_2$ - $C_{1-3}$ -alkyl,  $CO_2H$ ;
- 5 or  $R^2$  and  $R^3$  when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring containing carbon atoms and optionally containing 1 or 2 heteroatoms selected from O, S or N, wherein the ring is unsubstituted or substituted with 1 to 4 substituents independently selected from the group consisting of halogen, -CN, - $NO_2$ , OH, oxo,  $C_{1-3}$ -alkyl, halo- $C_{1-3}$ -alkyl, O- $C_{1-3}$ -alkyl, O-halo- $C_{1-3}$ -alkyl,  $SO_2$ - $C_{1-3}$ -alkyl,  $CO_2H$ ;
- 10  $R^4$  is selected from H,  $C_{1-6}$ -alkyl,  $C_{1-6}$ -acyl,  $C_{2-6}$ -alkenyl,  $C_{3-8}$ -cycloalkyl and  $C_{3-8}$ -heterocycloalkyl, wherein alkyl, acyl, alkenyl, cycloalkyl and heterocycloalkyl are optionally substituted with 1 to 5 substituents independently selected from halogen, -CN, OH, oxo,  $C_{1-3}$ -alkyl, halo- $C_{1-3}$ -alkyl, O- $C_{1-3}$ -alkyl, O-halo- $C_{1-3}$ -alkyl;
- $R^5$  and  $R^6$  and  $R^{5'}$  and  $R^{6'}$  are independently selected from H, halogen,  $C_{1-6}$ -alkyl,  $NH_2$ ,  $NHC_{1-6}$ -alkyl,  $N(C_{1-6}\text{-alkyl})_2$ ,  $C_{0-6}$ -alkylene- $C(=O)NH_2$ ;
- 15 or  $R^5$  and  $R^6$  and  $R^{5'}$  and  $R^{6'}$  independently when taken together with the carbon to which they are attached complete a 3- to 8-membered ring containing carbon atoms and optionally containing 1 or 2 heteroatoms selected from O, S or N, wherein the ring is unsubstituted or substituted with 1 to 4 substituents independently selected from the group consisting of halogen, -CN, - $NO_2$ , OH, oxo,  $C_{1-3}$ -alkyl, halo- $C_{1-3}$ -alkyl, O- $C_{1-3}$ -alkyl, O-halo- $C_{1-3}$ -alkyl,  $SO_2$ - $C_{1-3}$ -alkyl,  $CO_2H$ ;
- 20 or  $R^5$  and  $R^{5'}$  and  $R^6$  and  $R^{6'}$  independently when taken together with the two adjacent carbon to which they are attached complete a 3- to 8-membered ring containing carbon atoms and optionally containing 1 or 2 heteroatoms selected from O, S or N, wherein the ring is unsubstituted or substituted with 1 to 4 substituents independently selected from the group consisting of halogen, -CN, - $NO_2$ , OH, oxo,  $C_{1-3}$ -alkyl, halo- $C_{1-3}$ -alkyl, O- $C_{1-3}$ -alkyl, O-halo- $C_{1-3}$ -alkyl,  $SO_2$ - $C_{1-3}$ -alkyl,  $CO_2H$ ;
- 25  $R^7$  is selected from a 6-membered aryl and 5- or 6-membered heteroaryl, wherein aryl and heteroaryl are optionally substituted with 1 to 4 substituents independently selected from halogen, -CN, - $NO_2$ , OH,  $C_{1-6}$ -alkyl, O- $C_{1-6}$ -alkyl,  $C_{3-6}$ -cycloalkyl, O- $C_{3-6}$ -cycloalkyl,  $C_{3-6}$ -heterocycloalkyl, O- $C_{3-6}$ -heterocycloalkyl,  $SO_y$ - $C_{1-6}$ -alkyl,  $CO_2H$ ,  $C(=O)O$ - $C_{1-6}$ -alkyl, 6- to 10-membered aryl, 5- or 10-membered heteroaryl, O-(6- to 10-membered aryl) and O-(5- or 10-membered heteroaryl), wherein
- 30 alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are optionally substituted with 1 to 5 substituents independently selected from halogen, -CN, - $NO_2$ , OH,  $R^{13}$ ,  $OR^{13}$ ,  $CO_2R^{11}$ ,  $NR^{11}R^{12}$ ,  $C(=O)R^{11}$ ,  $C(=S)R^{11}$ ,  $C(=O)NR^{11}R^{12}$ ,  $NR^{11}C(=O)NR^{11}R^{12}$ ,
- 35

NR<sup>11</sup>C(=O)OR<sup>13</sup>, OC(=O)NR<sup>11</sup>R<sup>12</sup>, C(=S)NR<sup>11</sup>R<sup>12</sup>, NR<sup>11</sup>C(=S)NR<sup>11</sup>R<sup>12</sup>, NR<sup>11</sup>C(=S)OR<sup>13</sup>,  
 OC(=S)NR<sup>11</sup>R<sup>12</sup>; SO<sub>y</sub>-C<sub>1-6</sub>-alkyl, SO<sub>y</sub>-halo-C<sub>1-6</sub>-alkyl, SR<sup>11</sup>, SO<sub>x</sub>R<sup>13</sup>, SO<sub>3</sub>R<sup>11</sup>,  
 SO<sub>2</sub>NR<sup>11</sup>R<sup>12</sup>, NR<sup>11</sup>SO<sub>2</sub>R<sup>13</sup>, NR<sup>11</sup>SO<sub>2</sub>NR<sup>11</sup>R<sup>12</sup>;


- 5 R<sup>8</sup> is selected from H, -CN, -NO<sub>2</sub>, C<sub>1-10</sub>-alkyl, C<sub>2-10</sub>-alkenyl, C<sub>2-10</sub>-alkynyl, C<sub>0-10</sub>-alkylene-C<sub>3-10</sub>-  
 cycloalkyl, C<sub>0-10</sub>-alkylene-C<sub>3-10</sub>-heterocycloalkyl, C<sub>0-10</sub>-alkylene-(5 to 10-membered  
 heteroaryl), C<sub>0-10</sub>-alkylene-(6 to 10-membered aryl), C<sub>0-10</sub>-alkylene-(6 to 10-membered  
 heteroaryl), C<sub>0-10</sub>-alkylene-OR<sup>11</sup>, C<sub>0-10</sub>-alkylene-CO<sub>2</sub>R<sup>11</sup>, C<sub>0-10</sub>-alkylene-C(=O)NR<sup>11</sup>R<sup>12</sup>, C<sub>0-10</sub>-  
 alkylene-C(=S)NR<sup>11</sup>R<sup>12</sup>, C<sub>0-10</sub>-alkylene-C(=O)NR<sup>11</sup>SO<sub>2</sub>R<sup>13</sup>, C<sub>0-10</sub>-alkylene-  
 C(=S)NR<sup>11</sup>SO<sub>2</sub>R<sup>11</sup>, C<sub>0-10</sub>-alkylene-C(=O)R<sup>11</sup>, C<sub>0-10</sub>-alkylene-C(=S)R<sup>11</sup>, C<sub>0-10</sub>-alkylene-SR<sup>11</sup>,  
 10 C<sub>0-10</sub>-alkylene-SO<sub>x</sub>-R<sup>13</sup>, C<sub>0-10</sub>-alkylene-SO<sub>3</sub>R<sup>11</sup>, C<sub>0-10</sub>-alkylene-SO<sub>2</sub>NR<sup>11</sup>R<sup>12</sup>, C<sub>0-10</sub>-alkylene-  
 NR<sup>11</sup>C(=O)R<sup>11</sup>, C<sub>0-10</sub>-alkylene-NR<sup>11</sup>C(=S)R<sup>11</sup>, C<sub>0-10</sub>-alkylene-NR<sup>11</sup>SO<sub>2</sub>R<sup>11</sup>, C<sub>0-10</sub>-alkylene-  
 NR<sup>11</sup>C(=O)NR<sup>11</sup>R<sup>12</sup>, C<sub>0-10</sub>-alkylene-NR<sup>11</sup>C(=S)NR<sup>11</sup>R<sup>12</sup>, C<sub>0-10</sub>-alkylene-NR<sup>11</sup>-SO<sub>2</sub>-NR<sup>11</sup>R<sup>12</sup>,  
 C<sub>0-10</sub>-alkylene-NR<sup>11</sup>R<sup>12</sup>, wherein alkyl, alkenyl, alkynyl, alkylene, cycloalkyl,  
 heterocycloalkyl, aryl and heteroaryl is unsubstituted or substituted with 1 to 7  
 15 substituents independently selected from the group consisting of oxo, CN, -NO<sub>2</sub>, OR<sup>11</sup>, O-  
 C<sub>2-6</sub>-alkylene-OR<sup>11</sup>, C<sub>1-6</sub>-alkyl, halo-C<sub>1-6</sub>-alkyl, halogen, CO<sub>2</sub>R<sup>11</sup>, CONR<sup>11</sup>R<sup>12</sup>,  
 CONR<sup>11</sup>SO<sub>2</sub>R<sup>11</sup>, COR<sup>11</sup>, SO<sub>x</sub>R<sup>11</sup>, SO<sub>3</sub>H, PO(OH)<sub>2</sub>, SO<sub>2</sub>NR<sup>11</sup>R<sup>12</sup>, NR<sup>11</sup>COR<sup>11</sup>, NR<sup>11</sup>SO<sub>2</sub>R<sup>11</sup>,  
 NR<sup>11</sup>-CO-NR<sup>11</sup>R<sup>12</sup>, NR<sup>11</sup>-SO<sub>2</sub>-NR<sup>11</sup>R<sup>12</sup>, C<sub>3-10</sub>-cycloalkyl, O-C<sub>3-10</sub>-cycloalkyl, C<sub>3-10</sub>-  
 heterocycloalkyl, O-C<sub>3-10</sub>-heterocycloalkyl and NR<sup>11</sup>R<sup>12</sup>;
- 20 R<sup>9</sup> is selected from C<sub>1-10</sub>-alkyl, C<sub>2-10</sub>-alkenyl, C<sub>2-10</sub>-alkynyl, C<sub>0-10</sub>-alkylene-C<sub>3-10</sub>-cycloalkyl, C<sub>0-10</sub>-  
 alkylene-C<sub>3-10</sub>-heterocycloalkyl, C<sub>0-10</sub>-alkylene-(5- to 10-membered heteroaryl), C<sub>0-10</sub>-  
 alkylene-(6- to 10-membered aryl), C<sub>0-10</sub>-alkylene-(6- to 10-membered heteroaryl), C<sub>0-10</sub>-  
 alkylene-OR<sup>11</sup>, C<sub>0-10</sub>-alkylene-CO<sub>2</sub>R<sup>11</sup>, C<sub>0-10</sub>-alkylene-C(=O)NR<sup>11</sup>R<sup>12</sup>, C<sub>0-10</sub>-alkylene-  
 C(=S)NR<sup>11</sup>R<sup>12</sup>, C<sub>0-10</sub>-alkylene-C(=O)NR<sup>11</sup>SO<sub>2</sub>R<sup>13</sup>, C<sub>0-10</sub>-alkylene-C(=S)NR<sup>11</sup>SO<sub>2</sub>R<sup>11</sup>, C<sub>0-10</sub>-  
 25 alkylene-C(=O)R<sup>11</sup>, C<sub>0-10</sub>-alkylene-C(=S)R<sup>11</sup>, C<sub>0-10</sub>-alkylene-SR<sup>11</sup>, C<sub>0-10</sub>-alkylene-SO<sub>x</sub>R<sup>13</sup>,  
 C<sub>0-10</sub>-alkylene-SO<sub>3</sub>R<sup>11</sup>, C<sub>0-10</sub>-alkylene-SO<sub>2</sub>NR<sup>11</sup>R<sup>12</sup>, C<sub>0-10</sub>-alkylene-NR<sup>11</sup>C(=O)R<sup>11</sup>, C<sub>0-10</sub>-  
 alkylene-NR<sup>11</sup>C(=S)R<sup>11</sup>, C<sub>0-10</sub>-alkylene-NR<sup>11</sup>SO<sub>2</sub>R<sup>13</sup>, C<sub>0-10</sub>-alkylene-NR<sup>11</sup>C(=O)NR<sup>11</sup>R<sup>12</sup>, C<sub>0-10</sub>-  
 alkylene-NR<sup>11</sup>C(=S)NR<sup>11</sup>R<sup>12</sup>, C<sub>0-10</sub>-alkylene-NR<sup>11</sup>SO<sub>2</sub>NR<sup>11</sup>R<sup>12</sup>, C<sub>0-10</sub>-alkylene-NR<sup>11</sup>R<sup>12</sup>,  
 wherein alkyl, alkenyl, alkynyl, alkylene, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is  
 30 unsubstituted or substituted with 1 to 7 substituents independently selected from the  
 group consisting of oxo, CN, -NO<sub>2</sub>, OR<sup>11</sup>, O-C<sub>2-6</sub>-alkylene-OR<sup>11</sup>, C<sub>1-6</sub>-alkyl, halo-C<sub>1-6</sub>-alkyl,  
 halogen, CO<sub>2</sub>R<sup>11</sup>, C(=O)NR<sup>11</sup>R<sup>12</sup>, C(=O)NR<sup>11</sup>SO<sub>2</sub>R<sup>11</sup>, C(=O)R<sup>11</sup>, SR<sup>11</sup>, SO<sub>x</sub>R<sup>11</sup>, SO<sub>3</sub>R<sup>11</sup>,  
 P(=O)(OR<sup>11</sup>)<sub>2</sub>, SO<sub>2</sub>NR<sup>11</sup>R<sup>12</sup>, NR<sup>11</sup>C(=O)R<sup>11</sup>, NR<sup>11</sup>SO<sub>2</sub>R<sup>13</sup>, NR<sup>11</sup>C(=O)NR<sup>11</sup>R<sup>12</sup>,  
 NR<sup>11</sup>SO<sub>2</sub>NR<sup>11</sup>R<sup>12</sup>, C<sub>3-10</sub>-cycloalkyl, O-C<sub>3-10</sub>-cycloalkyl, C<sub>3-10</sub>-heterocycloalkyl, O-C<sub>3-10</sub>-  
 35 heterocycloalkyl and NR<sup>11</sup>R<sup>12</sup>;

- 5  $R^{11}$  is independently selected from H,  $C_{1-6}$ -alkyl,  $C_{0-6}$ -alkylene- $C_{3-10}$ -cycloalkyl and  $C_{0-6}$ -alkylene- $C_{3-10}$ -heterocycloalkyl, wherein alkyl, alkylene, cycloalkyl and heterocycloalkyl is unsubstituted or substituted with 1 to 6 substituents independently selected from the group consisting of halogen, -CN, OH, oxo,  $C_{1-3}$ -alkyl, halo- $C_{1-3}$ -alkyl, O- $C_{1-3}$ -alkyl, O-halo- $C_{1-3}$ -alkyl,  $NH_2$ ,  $NH(C_{1-3}\text{-alkyl})$ ,  $N(C_{1-3}\text{-alkyl})_2$ ,  $C_{3-6}$ -heterocycloalkyl,  $C_{3-6}$ -cycloalkyl,  $SO_2\text{-NHC}_{1-3}\text{-alkyl}$ ,  $SO_2\text{-N}(C_{1-3}\text{-alkyl})_2$  and  $SO_2\text{-C}_{1-3}\text{-alkyl}$ , wherein cycloalkyl and heterocycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of F, OH, oxo,  $CH_3$ ,  $CHF_2$  and  $CF_3$ ;
- 10  $R^{12}$  is independently selected from H,  $C_{1-6}$ -alkyl, halo- $C_{1-6}$ -alkyl and  $C_{3-6}$ -cycloalkyl;
- 15 or  $R^{11}$  and  $R^{12}$  when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring containing carbon atoms and optionally containing 1 or 2 heteroatoms selected from O, S or N, wherein the ring is unsubstituted or substituted with 1 to 4 substituents independently selected from the group consisting of halogen, -CN, - $NO_2$ , OH, oxo,  $C_{1-3}$ -alkyl, halo- $C_{1-3}$ -alkyl, O- $C_{1-3}$ -alkyl, O-halo- $C_{1-3}$ -alkyl,  $SO_2\text{-C}_{1-3}\text{-alkyl}$ ,  $CO_2H$ ;
- 20  $R^{13}$  is independently selected from  $C_{1-6}$ -alkyl,  $C_{0-6}$ -alkylene- $C_{3-10}$ -cycloalkyl and  $C_{0-6}$ -alkylene- $C_{3-10}$ -heterocycloalkyl, wherein alkyl, alkylene, cycloalkyl and heterocycloalkyl is unsubstituted or substituted with 1 to 6 substituents independently selected from the group consisting of halogen, -CN, OH, oxo,  $C_{1-3}$ -alkyl, halo- $C_{1-3}$ -alkyl, O- $C_{1-3}$ -alkyl, O-halo- $C_{1-3}$ -alkyl,  $NH_2$ ,  $NH(C_{1-3}\text{-alkyl})$ ,  $N(C_{1-3}\text{-alkyl})_2$ ,  $C_{3-6}$ -heterocycloalkyl,  $C_{3-6}$ -cycloalkyl,  $SO_2\text{-NHC}_{1-3}\text{-alkyl}$ ,  $SO_2\text{-N}(C_{1-3}\text{-alkyl})_2$  and  $SO_2\text{-C}_{1-3}\text{-alkyl}$ , wherein cycloalkyl and heterocycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of F, OH, oxo,  $CH_3$ ,  $CHF_2$  and  $CF_3$ ;
- 25 n is selected from 0 and 1;
- x is independently selected from 1 and 2;
- y is independently selected from 0, 1 and 2;


30 and wherein optionally  $R^1$  is connected to one residue selected from  $R^2$ ,  $R^3$ ,  $R^8$ ,  $R^9$ ,  $R^{10}$  or  $R^{12}$  to form a 5 to 8-membered heterocycle, which is optionally substituted with 1 to 4 substituents independently selected from the group consisting of halogen, -CN, - $NO_2$ , OH, oxo,  $C_{1-3}$ -alkyl, halo- $C_{1-3}$ -alkyl, O- $C_{1-3}$ -alkyl, O-halo- $C_{1-3}$ -alkyl,  $SO_2\text{-C}_{1-3}\text{-alkyl}$ ,  $CO_2H$ ;

or a tautomer, N-oxide, solvate, formulation and pharmaceutically acceptable salt thereof.


- 35 2. The compounds according to claim 1, wherein  
X is selected from



preferably X is selected from



3. The compounds according to claim 1 or 2, wherein n is 0.
4. The compounds according to any one of the preceding claims, which are represented by the formula




wherein


$\text{R}^{20}$  is selected from  $\text{C}_{1-4}$ -alkyl and  $\text{C}_{3-6}$ -cycloalkyl, wherein alkyl and cycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of F or Me;

$\text{R}^{21}$  is selected from F, Cl, OH, Me, OMe,  $\text{CHF}_2$ ,  $\text{CF}_3$ ,  $\text{OCHF}_2$ ,  $\text{OCF}_3$ ; and


Y is selected from nitrogen or carbon.

5. The compounds according to any one of the preceding claims, which are selected from the group consisting of






6. The compounds according to any one of the preceding claims, which are selected from
- (-)-*N*-Methyl-*N*-(4-methyl-5-(*S*-methylsulfonimidoyl)thiazol-2-yl)-2-(4-(pyridin-2-yl)phenyl)acetamide,
- (-)-(*S*)-2-(2',5'-Difluoro-[1,1'-biphenyl]-4-yl)-*N*-methyl-*N*-(4-methyl-5-(*S*-methylsulfonimidoyl)thiazol-2-yl)acetamide
- (-)-*N*-(5-(Cyclopropanesulfonimidoyl)-4-methylthiazol-2-yl)-*N*-methyl-2-(4-(pyridin-2-yl)phenyl)acetamide, and
- (-)-*N*-(5-(Cyclopropanesulfonimidoyl)-4-methylthiazol-2-yl)-2-(2',5'-difluoro-[1,1'-biphenyl]-4-yl)-*N*-methylacetamide.
7. A process for preparing the compounds according to Formula (Ia) and/or (Ib) according to any one of the preceding claims, the process comprising the steps
- a) providing a mixture comprising the compounds of the Formulae (Ia) and (Ib), such mixture being represented by the general Formula (I):



- b) separating and isolating the compounds of the Formula (Ia) and/or (Ib) using HPLC on a chiral column;
- wherein in the Formula (I) the substituents have the meaning as defined in the preceding claims.
8. The process according to claim 7, wherein Formula (Ia) and/or (Ib) is selected from



and in step b the separation on a chiral column affords pure (–)-enantiomer.

5

9. A process for preparing the compounds according to Formula (Ia) and/or (Ib) according to any one of the claims 1 to 6 by stereoselective synthesis and optionally subsequent preparative HPLC on a chiral column or precipitation with chiral compounds.
10. A compound according to any one of the claims 1 to 6 or obtainable by a process according to any one of the claims 7 to 9 for the use as a medicament.
11. A compound according to any one of the claims 1 to 6 or obtainable by a process according to any one of the claims 7 to 9 for use in the treatment or prophylaxis of a disease or disorder associated with viral infections.
12. A compound according to any one of the claims 1 to 6 or obtainable by a process according to any one of the claims 7 to 9 for use in the treatment or prophylaxis of a disease or disorder associated with viral infections caused by wild type or genetically engineered viruses which nucleic acids encode a helicase and/or primase and the virus is susceptible to said compounds based on the helicase and/or primase mechanism of action.
13. A compound according to any one of the claims 11 to 12, wherein the disease or disorder is associated with viral infections caused by herpes viruses.
14. A compound according to claim 13, wherein the disease or disorder is associated with viral infections caused by herpes simplex viruses.
15. A compound according to any one of the claims 1 to 6 or obtainable by a process according to any one of the claims 7 to 9 for use in the treatment or prophylaxis neurodegenerative diseases caused by viruses, such as Alzheimer's disease.

16. A compound according to any one of the claims 1 to 6 or obtainable by a process according to any one of the claims 7 to 9 for the use in the treatment and prophylaxis of herpes infections, in particular herpes simplex infections in patients displaying herpes disease such as herpes labialis, herpes genitalis and herpes-related keratitis, Alzheimer's disease, encephalitis, pneumonia, hepatitis or viral shedding; in patients with a suppressed immune system, such as AIDS patients, cancer patients, patients having a genetic or inherited immunodeficiency, transpant patients; in new-born children and infants; in herpes-positive patients, in particular herpes-simplex-positive patients, for suppressing recurrence or viral shedding (suppression therapy); patients, in particular in herpes-positive patients, in particular herpes-simplex-positive patients, who are resistant to nucleosidic antiviral therapy such as acyclovir, penciclovir, famciclovir, ganciclovir, valacyclovir and/or foscarnet or cidofovir.
17. A pharmaceutical composition comprising one or more of the compounds according to any one of the claims 1 to 6 or obtainable by a process according to any one of the claims 7 to 9 and at least one pharmaceutically acceptable carrier and/or excipient and/or at least one further active substance (antiviral active or immune modulating compounds) being effective in treating a disease or disorder associated with viral infections.

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/EP2018/077 022

Box No. IV Text of the abstract (Continuation of item 5 of the first sheet)

The present invention relates to novel antiviral compounds with specific stereoconfiguration, especially to specific novel enantiomers, to a process for their preparation and to their use as medicaments, in particular as antiviral medicaments.

